Xumeng Wang

Xumeng Wang

Auto-generated profile, based on publicly available information

Xumeng Wang

Department of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2018 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
JMJian Mo
Jian Mo
KHKangmao Huang
Kangmao Huang
XWXumeng Wang
Xumeng Wang
XSXinyu Sheng
Xinyu Sheng
QWQiang Wang
Qiang Wang
SFShunwu Fan
Shunwu Fan
Background: Orthopaedic surgeons must play an important role in the secondary prevention of fragility fractures; however, some surgeons are more aware than others of their responsibility regarding fracture prevention. The purpose of the present study was to identify which factors can lead to a higher sensitivity for fracture prevention. Methods: A cross-sectional survey was distributed to orthopaedic surgeons via online invitation or at academic conferences in China from July through October 2015. A total of 452 surgeons responded. As the primary outcome measure, we created a sensitivity scoring system for fracture prevention based on the respondents’ answers to 5 questions regarding behavior in the following areas: risk-factor evaluation, pharmacologic therapy, nonpharmacologic therapy, patient education, and follow-up. Multivariable linear regression and multivariable logistic regression analyses were used to identify factors related to surgeon sensitivity to fracture prevention. Results: Very few surgeons reported having received adequate training regarding fracture prevention or reading guidelines or other fracture prevention literature (22% and 30%, respectively). Most respondents initiated pharmacologic or nonpharmacologic therapy (82% and 75%, respectively) for the treatment of confirmed osteoporosis among patients with fragility fractures, but only half performed a risk-factor evaluation, patient education, or timely patient follow-up (51%, 52%, and 48%, respectively). In the multivariable linear regression model, the orthopaedic surgeon’s age (β = 0.09, p = 0.003), self-rated knowledge level regarding osteoporosis or related issues (β = 0.16, p < 0.001), self-perceived effectiveness in using preventive measures for patients with a fragility fracture (β = 0.62, p < 0.001), and use of clinical pathways for fragility fractures in his or her workplace (β = 1.24, p < 0.001) were independently associated with sensitivity scores for fracture prevention. Similar results were obtained from a multivariable logistic regression model. Conclusions: In China, the sensitivity of orthopaedic surgeons to the secondary prevention of fragility fractures is relatively low. Implementation of a comprehensive prevention approach and targeted continuing medical education are required to encourage surgeons to take greater responsibility for screening, treating, educating, and following their patients with fragility fractures.

20 March 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XWXumeng Wang
Xumeng Wang
JZJing Zhang
Jing Zhang
JYJimeng Yuan
Jimeng Yuan
LWLiping Wen
Liping Wen
TYTianxing Ying
Tianxing Ying
WWWeibin Wang
Weibin Wang
BRAF-targeted therapy is a promising strategy for thyroid cancer. However, its efficacy is limited by drug resistance. This study elucidates the role of fatty acid oxidation (FAO) in mediating adaptive resistance to BRAF V600E inhibition (BRAFi) in thyroid cancer. Through integrated transcriptomic and metabolomic analyses, we demonstrate that BRAFi by vemurafenib (PLX4032) significantly enhances FAO in thyroid cancer cells. The pharmacological inhibition of FAO via thioridazine (Thio) synergizes with BRAFi to suppress tumor growth in vitro, in vivo and in a patient-derived organoid. Mechanistically, this metabolic shift is driven by the upregulation of PGC1α, which enhances FAO. The consequent increase in intracellular acetyl-CoA reprograms the histone H3K9 acetylation (H3K9ac) landscape, thereby epigenetically activating pro-survival genes such as RUNX1. In addition, higher expression of RUNX1 correlates with poorer prognosis in thyroid cancer. Consistently, functional studies confirm RUNX1’s oncogenic role, as its knockdown reduces cell proliferation, migration, and invasion. In conclusion, our work reveals a metabolic-epigenetic axis underlying adaptive response to BRAFi and identifies RUNX1 as a novel oncogene in thyroid cancer.

14 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
WWWeibin Wang
Weibin Wang
XWXumeng Wang
Xumeng Wang
JZJing Zhang
Jing Zhang
JYJimeng Yuan
Jimeng Yuan
LWLiping Wen
Liping Wen
LTLisong Teng
Lisong Teng
BRAF-targeted therapy is a promising strategy for thyroid cancer. However, its efficacy is limited by drug resistance. This study elucidates the role of fatty acid oxidation (FAO) in mediating adaptive resistance to BRAF V600E inhibition (BRAFi) in thyroid cancer. Through integrated transcriptomic and metabolomic analyses, we demonstrate that BRAFi by vemurafenib (PLX4032) significantly enhances FAO in thyroid cancer cells. The pharmacological inhibition of FAO via thioridazine (Thio) synergizes with BRAFi to suppress tumor growth in vitro , in vivo and in a patient-derived organoid. Mechanistically, this metabolic shift is driven by upregulation of PGC1α, and increased FAO elevates intracellular acetyl-CoA levels, reprogramming histone H3K9 acetylation (H3K9ac) landscape, which epigenetically activates pro-survival genes including RUNX1. Higher expression of RUNX1 correlates with poorer prognosis in thyroid cancer. Functional studies confirm RUNX1's oncogenic role, as its knockdown reduces cell proliferation, migration, and invasion. In conclusion, our work reveals a metabolic-epigenetic axis underlying adaptive response to BRAFi and identify RUNX1 as a novel oncogene in thyroid cancer.